{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:25:51Z","timestamp":1783103151235,"version":"3.54.6"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PR9"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>NEO6860 is a TRPV1 antagonist when activated by capsaicin but not by heat or pH, developed to relieve pain without the adverse events reported with non\u2013modality-selective TRPV1 antagonists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The primary Objective of this study was to evaluate the analgesic efficacy and safety of NEO6860 after 1 day oral dosing in patients with Kellgren-Lawrence stage I, II or III osteoarthritis of the knee.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>This randomized, double-blinded, 3-period crossover, phase II study compared 1 day (2 doses) of NEO6860 (500 mg twice a day), placebo, and naproxen in 54 patients with osteoarthritis knee pain. Primary endpoint was reduction in pain intensity (PI) on Numerical Rating Scale after exercise, using the staircase test, 8 hours after dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Level of PI, compared with baseline, was numerically lower during NEO6860 and naproxen periods vs placebo at 3 and 24 hours, but not at 8 hours after first dose. A statistically significant effect for naproxen and a trend for NEO6860 were observed at 3 and 24 hours. Least square means' (95% confidence interval) change in PI at 24 hours was \u22120.67 (\u22121.09 to \u22120.26), \u22120.97 (\u22121.39 to \u22120.55), \u22120.29 (\u22120.71 to 0.13) for NEO6860, naproxen, and placebo, respectively. NEO6860 exposure was \u223c1.6 times higher compared with previous phase I. In this study, NEO6860 safety profile was less favorable than naproxen or placebo. Possibly NEO6860-related adverse events included: feel hot, headache, nausea, dizziness, fatigue, hypoaesthesia, and increased blood pressure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In this exploratory study, NEO6860 did not statistically significantly outperform placebo but showed an analgesic trend, without impacting body temperature and heat pain perception. Further studies are warranted to explore the potential of NEO6860 in other pain indications. We intent to optimize the dose and evaluate analgesic synergism with other mechanism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pr9.0000000000000696","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T21:34:41Z","timestamp":1540589681000},"page":"e696","source":"Crossref","is-referenced-by-count":54,"title":["NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain"],"prefix":"10.1097","volume":"3","author":[{"given":"Pierre","family":"Arsenault","sequence":"first","affiliation":[{"name":"Diex Recherche Sherbrooke, Sherbrooke, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chiche","sequence":"additional","affiliation":[{"name":"NEOMED Institute, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Brown","sequence":"additional","affiliation":[{"name":"NEOMED Institute, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Miller","sequence":"additional","affiliation":[{"name":"Consultant Exploratory Medicines, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roi","family":"Treister","sequence":"additional","affiliation":[{"name":"Faculty of Social Welfare and Health Sciences, The Cheryl Spencer Department of Nursing, University of Haifa, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Leff","sequence":"additional","affiliation":[{"name":"LLC, Chadds Ford, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Walker","sequence":"additional","affiliation":[{"name":"NEOMED Institute, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Katz","sequence":"additional","affiliation":[{"name":"Analgesic Solutions, Natick, MA, USA"},{"name":"Department of Anaesthesiology and Perioperative Medicine, Tufts University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11]]},"reference":[{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4314\/nqjhm.v17i1.12539","article-title":"Comparison of the effects of tens and sodium salicylate iontophoresis in the management of osteoarthritis of the knee","volume":"17","author":"Aiyejusunle","year":"2007","journal-title":"Nig Q J Hosp Med"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40256-016-0200-5","article-title":"Clinical pharmacology and cardiovascular safety of naproxen","volume":"17","author":"Angiolillo","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7326\/M14-1231","article-title":"Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis","volume":"162","author":"Bannuru","year":"2015","journal-title":"Ann Intern Med"},{"key":"R6-20230824","first-page":"364","article-title":"Rhythmic variations in pain perception in osteoarthritis of the knee","volume":"17","author":"Bellamy","year":"1990","journal-title":"J Rheumatol"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40264-014-0207-2","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications","volume":"37","author":"Bello","year":"2014","journal-title":"Drug Saf"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpain.2006.02.013","article-title":"Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials","volume":"11","author":"Bjordal","year":"2007","journal-title":"Eur J Pain"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/23328940.2015.1048045","article-title":"To not be hot when TRPV1 is not","volume":"2","author":"Blumberg","year":"2015","journal-title":"Temperature"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"2343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2013.03.003","article-title":"Targeting TRP channels for pain relief","volume":"716","author":"Brederson","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jpain.2017.01.009","article-title":"Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral NEO6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist","volume":"18","author":"Brown","year":"2017","journal-title":"J Pain"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/annrheumdis-2013-204660","article-title":"EULAR osteoarthritis ad hoc committee. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee","volume":"73","author":"Conaghan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/j.rehab.2016.07.354","article-title":"Quality of life for patient with knee osteoarthritis","volume":"59S","author":"Frioui Mahmoudi","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pain.2008.01.024","article-title":"Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans","volume":"36","author":"Gavva","year":"2008","journal-title":"PAIN"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.083915","article-title":"A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats","volume":"314","author":"Honore","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","article-title":"An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee","volume":"153","author":"Huggins","year":"2012","journal-title":"PAIN"},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1179\/jmt.2009.17.3.163","article-title":"Global rating of change scales: a review of strengths and weaknesses and considerations for design","volume":"17","author":"Kamper","year":"2009","journal-title":"J Man Manip Ther"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2036.2011.04629.x","article-title":"A randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain","volume":"33","author":"Krarup","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/13543776.2015.1008449","article-title":"Transient receptor potential vanilloid type 1 antagonists: a patent review (2011\u20132014)","volume":"3","author":"Lee","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13075-015-0845-5","article-title":"Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner","volume":"17","author":"Lowin","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cct.2013.12.007","article-title":"Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis","volume":"37","author":"Miller","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sjpain.2017.07.021","article-title":"A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis","volume":"17","author":"Mayorga","year":"2017","journal-title":"Scand J Pain"},{"key":"R26-20230824","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/1715163513481569","article-title":"Cardiovascular risk\u2014are all NSAIDs alike?","volume":"146","author":"Pawlosky","year":"2013","journal-title":"Can Pharm J (Ott)"},{"key":"R27-20230824","first-page":"S52","article-title":"The cardiovascular safety of nonsteroidal anti-inflammatory drugs: putting the evidence in perspective","volume":"66","author":"Quan","year":"2017","journal-title":"J Fam Pract"},{"key":"R28-20230824","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1016\/j.bmcl.2014.10.064","article-title":"Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates","volume":"24","author":"Rose","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"R29-20230824","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.pain.2011.01.051","article-title":"Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial","volume":"152","author":"Rowbotham","year":"2011","journal-title":"PAIN"},{"key":"R30-20230824","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clinthera.2005.01.002","article-title":"Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo","volume":"27","author":"Sheldon","year":"2005","journal-title":"Clin Ther"},{"key":"R31-20230824","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/JPR.S121455","article-title":"Development and preliminary validation of the focused analgesia selection test to identify accurate pain reporters","volume":"10","author":"Treister","year":"2017","journal-title":"J Pain Res"},{"key":"R32-20230824","first-page":"709","article-title":"Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners","volume":"112","author":"Van Manen","year":"2012","journal-title":"J Am Osteopath Assoc"},{"key":"R33-20230824","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/23328940.2015.1047721","article-title":"Feeling hot, feeling cold: TRP channels\u2014a great story unfolds","volume":"2","author":"Vetter","year":"2015","journal-title":"Temperature (Austin)"}],"container-title":["PAIN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01938936-201812000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:52:31Z","timestamp":1692892351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01938936-201812000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pr9.0000000000000696","relation":{},"ISSN":["2471-2531"],"issn-type":[{"value":"2471-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}